ArticleFrontiers in immunology2021
Editorial: Pathogens, Pathobionts, and Autoimmunity.
Linda A Spatz, Gregg J Silverman, Judith A James
Abstract readEditorial
In one paragraphArticle in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
3 authors.
Linda A SpatzDepartment of Molecular, Cellular, and Biomedical Sciences, CUNY School of Medicine, The City College of New York, New York, NY, United States.
Gregg J SilvermanDepartments of Medicine and Pathology, New York University (NYU) Grossman School of Medicine, New York, NY, United States.
Judith A JamesDepartment of Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States.
Funding
Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI PAUL G SPICER · 2013 to 2026
$68.2MOklahoma Rheumatic Disease Research Cores Center (Overall Application)P30AR073750 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JUDITH A JAMES · 2018 to 2026
$8.5MTranslational Center of Molecular Profiling in Preclinical and Established Lupus (COMPEL)P50AR070591 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI IZMIRLY, PETER · 2017 to 2021
$6.7MOklahoma ACE: Molecular Destruction of Autoimmune Disease to Aid Clinical Trail SuccessUM1AI144292 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JUDITH A JAMES · 2019 to 2026
$3.3MGut dysbiosis and tryptophan metabolism in lupusR01AI143313 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Laurence Morel, Gregg Joshua Silverman · 2019 to 2026
$3.3MDistance-based Panomic Analytics for Microbiome DataR01LM012517 · NLM · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ALEKSEYENKO, ALEXANDER V · 2018 to 2021
$1.3MNIAID NIH HHS R01 AI143313NIAID NIH HHS UM1 AI144292NIAMS NIH HHS P30 AR073750NIAMS NIH HHS P50 AR070591NIGMS NIH HHS U54 GM104938NLM NIH HHS R01 LM012517
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAutoimmunityBacteriaHumansVirusesautoimmune diseasesautoimmunitydysbiosismolecular mimicrypathobionts and gut microbiomepathogensSLEviruses
Identifiers
PMID34567014
PMCPMC8456017
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390